Cancer immunotherapy developer TCR² Therapeutics has raised $75 million in an IPO, which it will use for clinical trials to test a type of immunotherapy intended to treat a wider range of cancers than current cell therapies. Late Wednesday, TCR² priced its offering of 5 million shares at $15 apiece. The Cambridge, MA, company had […]
Original Article: TCR²’s IPO Raises $75M to Bring Cancer Cell Therapy to Solid Tumors